Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

New anthraquinone interacting with telomeric G-quadruplex DNA

Sep. 18, 1997

Role of osteoprotegerin in skeletal metabolism elucidated

Sep. 18, 1997

Highlights from the Japanese Society of Bone Metabolism Research

Sep. 17, 1997

Potential antipsychotics under development at Taisho/Nihon Nohyaku

Sep. 16, 1997

More on SE-205, a new MMP/TNF inhibitor from DuPont Merck

Sep. 16, 1997

NCI evaluates stability of SarCNU

Sep. 16, 1997

New compounds for influenza targeting cap-dependent endonuclease

Sep. 16, 1997

Merck Frosst reports further data on COX-2 inhibitor L-768277

Sep. 16, 1997

Potent and selective COX-2 inhibitors synthesized at Boehringer Ingelheim

Sep. 16, 1997

Glaxo Wellcome develops new influenza sialidase inhibitors

Sep. 16, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....